Biodesix Raises $12M More In Series E Funding

Boulder-based Biodesix, which is developing molecular diagnostic tests for the oncology market, has raised $12M in a Series E funding, the company said earlier this week. The funding came from existing investors. Biodesix says the new funding brings its total Series E funding to $27M, including two, earlier tranches, which came in 2013 and 2014. The company said the new funds go towards its technology platform, new product development, and expansion of its commercial efforts. More information »